Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer.

Haruhiko YamazakiTomoyuki YokoseHiroyuki HayashiHiroyuki IwasakiSachie OsanaiNobuyasu SuganumaHirotaka NakayamaKatsuhiko MasudoYasushi RinoMunetaka Masuda

Published in: Cancer chemotherapy and pharmacology (2018)

There was no correlation between the expression of VEGFR2 in tumor tissue and the clinical response to lenvatinib among patients with ATC. Further studies are necessary to elucidate the mechanism underlying the response to lenvatinib.

Keyphrases

vascular endothelial growth factor
poor prognosis
endothelial cells
long non coding rna